Doctors turn to a familial Alzheimer's genetic panel when a patient develops memory problems before age 65 or has close relatives who did, because that pattern points toward a rare, inherited form of the disease. The panel sequences three genes — APP, PSEN1, and PSEN2 — to look for a mutation that directly causes early-onset Alzheimer's rather than relying on symptoms alone. This differs from standard dementia workups because it targets a specific inherited cause, not just a diagnosis. Joint practice guidelines from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors state that this kind of diagnostic testing is most appropriate for patients with early-onset symptoms or a family history of early-onset disease, and that it should always be paired with genetic counseling before and after the test.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who Actually Qualifies for the Panel
- What the Panel Tests and What It Finds
- What a Negative Result Does Not Rule Out
- Testing Relatives Once a Mutation Is Confirmed
- Where APOE Testing Fits, and Where It Does Not
Who Actually Qualifies for the Panel
Doctors do not order this panel for every patient with new memory loss. It is reserved for a specific clinical picture: symptoms appearing before age 65, especially when combined with a family history suggesting the disease runs through multiple generations in a predictable pattern. Insurance medical policy, which mirrors the ACMG/NSGC criteria, spells out three scenarios where testing is approved.
According to Highmark's commercial medical policy, coverage applies when a patient has new-onset dementia before 65 with an unclear family history, a documented family history of early-onset autosomal-dominant dementia, or a first- or second-degree relative who already carries a known APP, PSEN1, or PSEN2 mutation. That third scenario matters for families already navigating a diagnosis. If a parent or sibling has tested positive for one of these mutations, a doctor can use that result to guide testing decisions for other relatives, rather than starting the genetic search from scratch each time.
What the Panel Tests and What It Finds
The panel sequences three genes tied to autosomal-dominant familial Alzheimer's: APP, PSEN1, and PSEN2. Autosomal-dominant means a single altered copy of one of these genes, inherited from either parent, is enough to cause the disease. Together, these three genes identify a causative mutation in roughly 60 to 80 percent of patients with confirmed early-onset familial Alzheimer's, according to ARUP Laboratories' test description. The three genes are not equally common causes.
Among families with a known genetic cause, PSEN1 mutations account for about 66 percent of cases, APP mutations for 16 to 20 percent, and PSEN2 mutations are the least frequent, according to a PMC review of the genes associated with early-onset Alzheimer's disease. PSEN2 also behaves differently once found: it shows reduced, not full, penetrance, meaning a person carrying the mutation is not guaranteed to develop the disease in their lifetime. This breakdown shapes how a doctor interprets a positive result. A PSEN1 finding is the most common and most clearly causative outcome. A PSEN2 finding still needs to be explained to the patient as a mutation that raises risk substantially without being a certainty.
What a Negative Result Does Not Rule Out
A clean panel result is not the same as ruling out familial Alzheimer's. A genetic cause remains unidentified in roughly 20 to 40 percent of early-onset familial cases even after testing, according to ARUP Laboratories. Part of the gap is technical.
The assay covers the coding regions of the three genes and the boundaries between introns and exons, the stretches of DNA flanking each gene's protein-coding segments. Some variant types fall outside what this method detects, so a mutation can exist in a gene the panel checks and still be missed by the specific technique used. For a family with a strong history of early-onset dementia but a negative panel, doctors generally continue to treat the family history itself as clinically meaningful, since the absence of a detectable mutation does not establish that the disease is not inherited.
Testing Relatives Once a Mutation Is Confirmed
Once a pathogenic variant is confirmed in a symptomatic patient, doctors can offer a narrower test to asymptomatic at-risk relatives: single-site testing that checks only for that specific known family mutation, rather than sequencing all three genes again. The Alzheimer's Association's genetic testing fact sheet describes this as available only after formal genetic counseling.
That counseling step is not optional paperwork. It covers the difference between a predictive result and a diagnostic one — a healthy relative who tests positive learns about future risk, not a current illness — along with how the result could affect insurance and employment. A relative considering this test is deciding whether to learn information that cannot currently be acted on medically, which is why counseling precedes the blood draw rather than following it.
Where APOE Testing Fits, and Where It Does Not
A separate gene, APOE, often comes up in the same conversation, but doctors use it for a different purpose. Standalone APOE genotyping is generally not recommended as part of a routine workup for new memory symptoms. Blue Cross NC's genetic testing policy notes that its diagnostic yield is low and that risk results are difficult to interpret for an individual patient; most insurers classify APOE testing for the common, late-onset form of Alzheimer's as investigational.
APOE has gained a newer, more specific role tied to treatment rather than diagnosis. FDA labeling for the anti-amyloid drugs lecanemab (Leqembi) and donanemab recommends APOE testing before starting treatment, because patients with two copies of the APOE4 variant face substantially higher risk of ARIA, a drug-related imaging abnormality involving brain swelling or bleeding, according to Iowa Medicaid's clinical criteria citing the FDA labeling. No FDA-authorized APOE test currently exists specifically for this purpose, so doctors weighing one of these treatments order APOE testing for a different reason than they would order the three-gene familial panel.
